SCHEMBL9832005

SCHEMBL9832005

O=c1[nH]ccc2ncnn12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 13/20 0.38
MAP2K1 Q02750 3/20 0.37
MAPK8 P45983 2/20 0.34
DYRK1A Q13627 2/20 0.34
CLK4 Q9HAZ1 2/20 0.34
DYRK1B Q9Y463 2/20 0.34
CHEK1 O14757 1/20 0.34
AURKA O14965 1/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34
MAP4K4 O95819 1/20 0.34
ABL1 P00519 1/20 0.34
NTRK1 P04629 1/20 0.34
LCK P06239 1/20 0.34
CSF1R P07333 1/20 0.34
RET P07949 1/20 0.34
MET P08581 1/20 0.34
PDGFRB P09619 1/20 0.34
PIM1 P11309 1/20 0.34
FGFR1 P11362 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL867071 0.68 KDR (0.35) ABL1KDRXDH
SCHEMBL9121031 0.68 MAP2K1 (0.37) MAP2K1MAPK8DYRK1ACLK4DYRK1B
SCHEMBL11939795 0.68 TDP1 (0.34) MAP2K1MAPK8DYRK1ACLK4DYRK1B
SCHEMBL18358350 0.65 CHEK1 (0.39) EGLN2MAP2K1MAPK8DYRK1ACLK4
SCHEMBL17873877 0.65 HAVCR2 (0.41) EGLN2MAP2K1MAPK8DYRK1ACLK4
SCHEMBL11883707 0.65 NUDT1 (0.41) EGLN2MAP2K1DYRK1ACLK4CHEK1
SCHEMBL557383 0.64 MAP2K1 (0.44) MAP2K1DYRK1ADYRK1BCHEK1MAP4K4
SCHEMBL3132349 0.62 USP2 (0.38) MAP2K1
SCHEMBL25664506 0.62 MAPK8 (0.35) MAPK8DYRK1ACLK4DYRK1B
SCHEMBL12335785 0.58 MAP2K1 (0.53) MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3489238-B1 PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS DART NEUROSCIENCE CAYMAN LTD (KY) 2021-10-13 EP claimed
US-12384787-B2 Fused heterocyclic compounds and their use as pest control agents PI INDUSTRIES LTD (IN) 2025-08-12 US disclosed
US-12351583-B2 Triazolopyrimidines based on thymine nucleobase and methods for producing them CHEMITERAS, INC. (JP) 2025-07-08 US disclosed
US-20220251094-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS PI INDUSTRIES LTD. (IN) 2022-08-11 US disclosed
US-20220194950-A1 TRIAZOLOPYRIMIDINES BASED ON THYMINE NUCLEOBASE AND METHODS FOR PRODUCING THEM TERA STONE CO., LTD (JP) 2022-06-23 US disclosed
EP-3950064-A1 THYMINE NUCLEOBASE-BASED TRIAZOLOPYRIMIDINES AND PRODUCTION METHOD THEREFOR Tera Stone Co., Ltd (JP) 2022-02-09 EP disclosed
EP-3489238-A1 PHARMACEUTICAL COMPOSITIONS OF 6H-PYRIDO[3,2-E][1,2,4]TRIAZOLO[1,5-C]PYRIMIDIN-5-ONE AND [1,2,4]TRIAZOLO[1,5-C]PTERIDIN-5(6H)-ONE DERIVATIVES AS PDE1 INHIBITORS FOR TREATING E.G. NEUROLOGICAL DISORDERS Dart NeuroScience (Cayman) Ltd (KY) 2019-05-29 EP disclosed
US-8575114-B2 SGLT-2 inhibitors, methods of making them, and uses thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2013-11-05 US disclosed
US-8575114-B2 SGLT-2 inhibitors, methods of making them, and uses thereof ALBANY MOLECULAR RESEARCH, INC. (US) 2013-11-05 US disclosed
US-20110237527-A1 SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-09-29 US disclosed
US-20110237527-A1 SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF ALBANY MOLECULAR RESEARCH, INC. (US) 2011-09-29 US disclosed
EP-0217748-B1 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof CIBA-GEIGY AG (CH) 1991-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351583-B2 Triazolopyrimidines based on thymine nucleobase and methods for producing them TYMP, DPYD, DTYMK EGLN2 3297/4885MAP2K1 1735/4885MAPK8 842/4885
US-20110237527-A1 SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF SLC5A2, SLC5A1, SLC10A1 EGLN2 1259/4885MAP2K1 1444/4885MAPK8 2206/4885
US-12384787-B2 Fused heterocyclic compounds and their use as pest control agents DDT, ACHE, KEAP1 EGLN2 2772/4885MAP2K1 3755/4885MAPK8 2709/4885
US-20220194950-A1 TRIAZOLOPYRIMIDINES BASED ON THYMINE NUCLEOBASE AND METHODS FOR PRODUCING THEM TYMP, DPYD, DTYMK EGLN2 3297/4885MAP2K1 1735/4885MAPK8 842/4885
US-20220251094-A1 FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS DDT, ACHE, KEAP1 EGLN2 2772/4885MAP2K1 3755/4885MAPK8 2709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.